Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States
Journal of Clinical Oncology2014Vol. 33(2), pp. 195–201
Citations Over TimeTop 10% of 2014 papers
A. Lindsay Frazier, Juliet Hale, Carlos Rodríguez‐Galindo, Ha Dang, Thomas A. Olson, Matthew J. Murray, James F. Amatruda, Claire Thornton, G. Suren Arul, Deborah F. Billmire, Furqan Shaikh, Farzana Pashankar, Sara Stoneham, Mark Krailo, James C. Nicholson
Abstract
Clinical trial data from two large national pediatric clinical trial organizations have produced a new evidence-based risk stratification of malignant pediatric GCTs that identifies a poor-risk group warranting intensified therapy.
Related Papers
- → Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A gynecologic oncology group study (a final report)(1985)168 cited
- → α-Fetoprotein in malignant germ cell tumors of the ovary(1990)47 cited
- → Retroperitoneal germ cell tumors in childhood. A clinical and pathologic study of 11 cases(1985)46 cited
- → Retroperitoneal Endodermal Sinus Tumor(2017)1 cited
- CT Diagnosis of Ovarian Germ Cell Tumors(2001)